Namhee Kwon
Overview
Explore the profile of Namhee Kwon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
534
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jakes R, Kwon N, Huynh L, Hwee J, Baylis L, Alfonso-Cristancho R, et al.
ERJ Open Res
. 2024 Aug;
10(4).
PMID: 39104949
Background And Aims: Real-world evidence characterising the burden of eosinophilic granulomatosis with polyangiitis (EGPA) in Europe is limited. The aim of this study was to characterise patients in a large...
2.
Jayne D, Terrier B, Hellmich B, Khoury P, Baylis L, Bentley J, et al.
ERJ Open Res
. 2024 Jan;
10(1).
PMID: 38196889
Background: The Mepolizumab in Relapsing or Refractory EGPA (MIRRA) trial (GSK ID: 115921/NCT02020889) demonstrated that mepolizumab increased remission time and reduced oral corticosteroid (OCS) use compared with placebo in patients...
3.
Khoury P, Akuthota P, Kwon N, Steinfeld J, Roufosse F
Mayo Clin Proc
. 2023 Jul;
98(7):1054-1070.
PMID: 37419574
Elevated eosinophil counts are implicated in multiple diseases, from relatively prevalent organ-specific disorders such as severe eosinophilic asthma, to rare multisystem disorders such as hypereosinophilic syndrome (HES) and eosinophilic granulomatosis...
4.
Terrier B, Jayne D, Hellmich B, Bentley J, Steinfeld J, Yancey S, et al.
ACR Open Rheumatol
. 2023 Jun;
5(7):354-363.
PMID: 37312233
Objective: To evaluate mepolizumab's efficacy in eosinophilic granulomatosis with polyangiitis (EGPA) with and without a vasculitic phenotype. Methods: The MIRRA study (NCT02020889/GSK ID: 115921) included adults with relapsing/refractory EGPA and...
5.
Ainsworth B, Chatburn E, Bansal A, Fulton O, Hamerlijnck D, Coleman C, et al.
ERJ Open Res
. 2023 Jun;
9(3).
PMID: 37260457
Introduction: Severe asthma is a complex, multidimensional disease. Optimal treatment, adherence and outcomes require shared decision-making, rooted in mutual understanding between patient and clinician. This study used a novel, patient-centred...
6.
Roufosse F, Butterfield J, Steinfeld J, Bentley J, von Maltzahn R, Kwon N, et al.
Front Med (Lausanne)
. 2023 Apr;
10:1035250.
PMID: 37064032
Background: Hypereosinophilic syndrome (HES) is characterized by persistent elevated blood and/or tissue eosinophil levels and eosinophil-mediated organ damage. Presentation is highly heterogenous; patients may experience symptoms affecting multiple organ systems....
7.
Kroes J, Alfonso-Cristancho R, Bansal A, Berret E, Bieksiene K, Bourdin A, et al.
ERJ Open Res
. 2023 Apr;
9(2).
PMID: 37020841
Background: An objective of the Severe Heterogeneous Asthma Registry, Patient-centered (SHARP) is to produce real-world evidence on a pan-European scale by linking nonstandardised, patient-level registry data. Mepolizumab has shown clinical...
8.
Hwee J, Huynh L, Du S, Kwon N, Jakes R, Alfonso-Cristancho R, et al.
Ann Allergy Asthma Immunol
. 2023 Mar;
130(6):768-775.
PMID: 36863663
Background: The burden of hypereosinophilic syndrome (HES) in Europe is not well characterized. Objective: To evaluate real-world patient characteristics, treatment patterns, clinical manifestations, and healthcare resource utilization for patients with...
9.
Strobel M, Alves D, Roufosse F, Antoun Z, Kwon N, Baylis L, et al.
J Patient Exp
. 2022 Dec;
9:23743735221143953.
PMID: 36530646
Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are driven by persistently high eosinophil numbers, causing damage to tissues and organs. As rare diseases, they are often underappreciated by...
10.
Pane F, Lefevre G, Kwon N, Bentley J, Yancey S, Steinfeld J
Front Immunol
. 2022 Sep;
13:935996.
PMID: 36091012
Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT02836496, identifier NCT02836496.